Incyte reports 81% bleeding reduction in VWD study
Incyte (NASDAQ:INCY) reported complete Phase 1/2 safety and efficacy data from 16 patients treated with latarcibart, an investigational Protein S-targeting antibody being developed for von Willebrand disease (VWD).










